Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma—An evidence‐based approach.

Autor: Rai, Sandeep1, Das, Nupur1, Gupta, Ritu1 drritu.laboncology@aiims.edu, Kumar, Lalit2, Sharma, Atul2, Singh, Saroj1, Prajapati, Vijay K.1
Zdroj: International Journal of Laboratory Hematology. Apr2023, Vol. 45 Issue 2, p179-186. 8p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje